Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 2, 2026, 1:43 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Suboxone Clear all
Completed Phase 3 Interventional

Buprenorphine and Naloxone for the Treatment of Opiate Dependence - 1

NCT00015171
View directory record Official record
Conditions
Heroin Dependence, Substance-Related Disorders
Interventions
Buprenorphine/naloxone
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years to 59 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 1997
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 15, 2017 · Synced Sep 2, 2026, 1:43 AM EDT
Completed Phase 4 Interventional Results available

Extended-Release Naltrexone vs. Buprenorphine for Opioid Treatment

NCT02032433
View directory record Official record
Conditions
Opioid Use Disorder
Interventions
Extended-Release Naltrexone, Buprenorphine-Naloxone
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
570 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
8
States / cities
Tarzana, California • Jacksonville, Florida • Rockville, Maryland + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 12, 2020 · Synced Sep 2, 2026, 1:43 AM EDT
Completed Phase 4 Interventional Results available

Starting Treatment With Agonist Replacement Therapies (START)

NCT00315341
View directory record Official record
Conditions
Opiate-related Disorders
Interventions
Buprenorphine/naloxone, Methadone
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older
Enrollment
1,269 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
9
States / cities
Los Angeles, California • Sacramento, California • San Francisco, California + 6 more
Source: ClinicalTrials.gov public record
Updated Jan 5, 2017 · Synced Sep 2, 2026, 1:43 AM EDT
Completed Phase 4 Interventional Results available

Buprenorphine Loading in the Emergency Department

NCT04283500
View directory record Official record
Conditions
Opioid-use Disorder
Interventions
Buprenorphine Naloxone
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 80 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 14, 2024 · Synced Sep 2, 2026, 1:43 AM EDT
Suspended No phase listed Observational Accepts healthy volunteers

Patients' Attitudes Toward and Experiences With Buprenorphine Treatment

NCT05121428
View directory record Official record
Conditions
Opioid-use Disorder, Acceptability of Health Care, Opioid-Related Disorders
Interventions
Not listed
Lead sponsor
Cambridge Health Alliance
Other
Eligibility
18 Years and older
Enrollment
817 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2027
U.S. locations
1
States / cities
Cambridge, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 10, 2025 · Synced Sep 2, 2026, 1:43 AM EDT
Not listed Phase 2 Interventional Accepts healthy volunteers

Interim Buprenorphine Treatment to Bridge Waitlist Delays: Stage II Evaluation

NCT03420313
View directory record Official record
Conditions
Opioid-use Disorder
Interventions
Buprenorphine/naloxone sublingual tablets
Drug
Lead sponsor
University of Vermont
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
1
States / cities
Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated May 2, 2019 · Synced Sep 2, 2026, 1:43 AM EDT
Withdrawn Phase 2 Interventional

Buprenorphine/Naloxone Treatment for Opioid Dependence-Experiment II-2 - 5

NCT00000330
View directory record Official record
Conditions
Heroin Dependence, Opioid-Related Disorders
Interventions
Opioid-Related Disorders
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated May 3, 2017 · Synced Sep 2, 2026, 1:43 AM EDT
Completed Not applicable Interventional

Bridging Active Heroin Users to Hepatitis C Treatment Using Buprenorphine - 1

NCT00249574
View directory record Official record
Conditions
Hepatitis C, Heroin Dependence
Interventions
Buprenorphine/naloxone, pegInterferon
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years to 80 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
1
States / cities
Oakland, California
Source: ClinicalTrials.gov public record
Updated Jan 15, 2017 · Synced Sep 2, 2026, 1:43 AM EDT
Completed Phase 4 Interventional

Determine the Safety of a Sublingual Tablet Formulation of Buprenorphine and Naloxone by Extending the Combination Tablet Availability to Physicians in Office-Based Practice

NCT00007527
View directory record Official record
Conditions
Opiate Dependence
Interventions
naloxone, buprenorphine
Drug
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
15 Years and older
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2002
U.S. locations
2
States / cities
New York, New York • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jan 20, 2009 · Synced Sep 2, 2026, 1:43 AM EDT
Completed Phase 2 Interventional Results available

Low Dose Naltrexone-buprenorphine Transfer to Vivitrol Injection in Opioid Dependence

NCT01690546
View directory record Official record
Conditions
Opiate Dependence
Interventions
very low dose naltrexone, extended release naltrexone, buprenorphine/naloxone
Drug
Lead sponsor
Paolo Mannelli
Other
Eligibility
18 Years to 65 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated May 31, 2016 · Synced Sep 2, 2026, 1:43 AM EDT
Withdrawn Phase 2 Interventional

Buprenorphine/Naloxone Treatment for Opioid Dependence-Experiment I(2) - 2

NCT00000327
View directory record Official record
Conditions
Heroin Dependence, Opioid-Related Disorders
Interventions
Heroin Dependence
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 62 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated May 3, 2017 · Synced Sep 2, 2026, 1:43 AM EDT
Completed Phase 1 Interventional Results available

A Study to Assess the Effect of a Single Dose of ASP8062 on the Multiple Dose Safety, Tolerability and Pharmacokinetics of Buprenorphine/Naloxone in Participants With Opioid Use Disorder

NCT04447287
View directory record Official record
Conditions
Opioid Use Disorder
Interventions
ASP8062, Placebo ASP8062, buprenorphine/naloxone
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Nov 20, 2024 · Synced Sep 2, 2026, 1:43 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effects of Buprenorphine/Naloxone Administered in Different Ways For Treating Opioid Dependence

NCT00134914
View directory record Official record
Conditions
Opioid-Related Disorders
Interventions
Buprenorphine
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years to 55 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1996 – 1998
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 11, 2017 · Synced Sep 2, 2026, 1:43 AM EDT
Terminated No phase listed Observational

The Effects of Opioid Taper on Opioid-Induced Hyperalgesia

NCT03063905
View directory record Official record
Conditions
Buprenorphine, Pain
Interventions
Buprenorphine
Drug
Lead sponsor
Georgetown University
Other
Eligibility
18 Years to 50 Years
Enrollment
15 participants
Timeline
2017 – 2018
U.S. locations
2
States / cities
Rockville, Maryland • Silver Spring, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 20, 2018 · Synced Sep 2, 2026, 1:43 AM EDT
Completed Phase 4 Interventional Results available

Rapid Initiation of Drug Treatment Engagement

NCT03908437
View directory record Official record
Conditions
Opioid-use Disorder, Overdose
Interventions
buprenorphine/naloxone
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 2, 2024 · Synced Sep 2, 2026, 1:43 AM EDT
Completed Phase 3 Interventional Results available

Prescription Opioid Addiction Treatment Study (POATS)

NCT00316277
View directory record Official record
Conditions
Opiate Dependence, Substance-related Disorders, Opioid-related Disorders
Interventions
Standard Medical Management (SMM) of Prescription Opiate Abuse, Enhanced Medical Management (EMM) of Prescription Opiate Abuse
Behavioral
Lead sponsor
Mclean Hospital
Other
Eligibility
18 Years and older
Enrollment
653 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2013
U.S. locations
12
States / cities
Los Angeles, California • San Francisco, California • Lawrenceburg, Indiana + 8 more
Source: ClinicalTrials.gov public record
Updated Feb 5, 2013 · Synced Sep 2, 2026, 1:43 AM EDT
Completed Phase 2 Interventional

Buprenorphine/Naloxone for Treatment of Opiate Dependence - 9

NCT00000344
View directory record Official record
Conditions
Opioid-Related Disorders
Interventions
Buprenorphine/naloxone
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
21 Years to 50 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2000
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jan 11, 2017 · Synced Sep 2, 2026, 1:43 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Effects of Buprenorphine/Naloxone in Treating Opioid Dependent Individuals Who Are Maintained on Methadone

NCT00000243
View directory record Official record
Conditions
Opioid-Related Disorders
Interventions
Buprenorphine
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years to 55 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2004
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 11, 2017 · Synced Sep 2, 2026, 1:43 AM EDT
Not listed Phase 2 Interventional

Sublingual Buprenorphine for Chronic Pain

NCT00612287
View directory record Official record
Conditions
Chronic Pain
Interventions
buprenorphine
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years to 70 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 6, 2009 · Synced Sep 2, 2026, 1:43 AM EDT
Withdrawn Phase 2 Interventional

Buprenorphine/Naloxone Treatment for Opioid Dependence-Experiment III) - 3

NCT00000328
View directory record Official record
Conditions
Heroin Dependence, Opioid-Related Disorders
Interventions
Opioid-Related Disorders
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated May 3, 2017 · Synced Sep 2, 2026, 1:43 AM EDT
Completed Phase 1 Interventional

A Study to Assess the Drug-drug Interaction of BMS 663068 With Methadone and Also With Buprenorphine/Naloxone

NCT02666001
View directory record Official record
Conditions
Infection, Human Immunodeficiency Virus
Interventions
BMS-663068, Methadone, Buprenorphine and Norbuprenorphine
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 65 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
2
States / cities
Orlando, Florida • Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Aug 8, 2017 · Synced Sep 2, 2026, 1:43 AM EDT
Completed Phase 3 Interventional Results available

Efficacy of BNX Sublingual Tablets Versus BNX Sublingual Film for Treatment of Opioid-Dependent Adults

NCT01908842
View directory record Official record
Conditions
Opioid Dependence, on Agonist Therapy
Interventions
BNX sublingual tablets, BNX sublingual film, Buprenorphine
Drug
Lead sponsor
Orexo AB
Industry
Eligibility
18 Years to 65 Years
Enrollment
759 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
36
States / cities
Baldwin County, Alabama • Houston County, Alabama • Maricopa, Arizona + 33 more
Source: ClinicalTrials.gov public record
Updated May 9, 2017 · Synced Sep 2, 2026, 1:43 AM EDT
Completed Phase 2 Interventional Results available

Incomplete Response in Late-Life Depression: Getting to Remission With Buprenorphine

NCT02176291
View directory record Official record
Conditions
Depression, Major Depressive Disorder
Interventions
Buprenorphine, Placebo
Drug
Lead sponsor
Jordan F. Karp
Other
Eligibility
50 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 28, 2018 · Synced Sep 2, 2026, 1:43 AM EDT
Completed Not applicable Interventional Results available

OXD01 in Combination With Sublingual Buprenorphine/Naloxone for Treatment of Opioid Use Disorder

NCT04948307
View directory record Official record
Conditions
Opioid-use Disorder
Interventions
OXD01 digital therapy, Standard of Care
Device · Other
Lead sponsor
Orexo AB
Industry
Eligibility
18 Years to 65 Years
Enrollment
437 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
21
States / cities
Birmingham, Alabama • Oceanside, California • San Diego, California + 17 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2025 · Synced Sep 2, 2026, 1:43 AM EDT